KIA
CLDX icon

Kopp Investment Advisors’s Celldex Therapeutics CLDX Stock Holding History

Kopp Investment Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-579
Closed -$219K – 68
2015
Q2 		$219K Buy
579
+27
+5% +$10.7K 0.1% 63
2015
Q1 		$231K Buy
+552
New +$197K 0.1% 66
2013
Q4 		– Sell
-4,850
Closed -$2.58M – 69
2013
Q3 		$2.58M Sell
4,850
-4,144
-46% -$1.42M 0.95% 24
2013
Q2 		$2.11M Buy
+8,994
New +$1.77M 0.82% 29

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kopp Investment Advisors's CLDX Position: Q3 2015 in Review

Kopp Investment Advisors sold out of Celldex Therapeutics (CLDX) in Q3 2015, closing a stake of 579 shares — an estimated $219K sold.

Kopp Investment Advisors first reported a position in CLDX in Q2 2013 and held it in 4 quarters. The position peaked at $2.58M in Q3 2013. 162 funds tracked by Wall St. Rank hold CLDX as of Q3 2015.

  • Kopp Investment Advisors reported no remaining Celldex Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Kopp Investment Advisors sold 579 Celldex Therapeutics shares in Q3 2015, an estimated $219K.
  • Kopp Investment Advisors first reported a position in Celldex Therapeutics in Q2 2013 and held it in 4 quarters.
  • Kopp Investment Advisors's Celldex Therapeutics position peaked at $2.58M in Q3 2013.
  • 162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2015.

Based on Kopp Investment Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.